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Summary
Objectives: The role of calcium phosphate and pyrophosphate crystals in osteoarthritis (OA) is unclear: are they a symptom of the damage
that occurs to the joint or a key intermediate in the progression of inﬂammation and joint damage that occurs in OA? The proinﬂammatory and
catabolic response of synthetic calcium phosphate and pyrophosphate crystals and crystals extracted from human osteoarthritic knee carti-
lage has been investigated. The crystal forms eliciting a response have been characterised allowing a comparison of the biological effects of
synthetic and native calcium crystals on human osteoarthritic chondrocytes and synoviocytes to be carried out.
Methods: Calcium phosphate and pyrophosphate crystals were synthesised in vitro and their crystal forms characterised by X-ray powder
diffraction (XRPD). The inorganic crystalline material present in human osteoarthritic cartilage was extracted and its structural composition
elucidated by XRPD. These crystals were applied to human primary osteoarthritic chondrocytes and synoviocytes and the production of proin-
ﬂammatory and catabolic mediators measured.
Results: The crystals extracted from human osteoarthritic knee cartilage were identiﬁed as consisting of a mixture of monoclinic and triclinic
calcium pyrophosphate dihydrate (m-CPPD and t-CPPD). These crystals elicited an inﬂammatory and catabolic response in human primary
osteoarthritic chondrocytes and synoviocytes as measured by an increase in nitric oxide (NO), matrix metalloproteinase 13 (MMP-13) and
prostaglandin E2 (PGE2) production. NO, MMP-13 and PGE2 production was also increased when the synthetic calcium hydrogen phosphate
dihydrate (DCPD) and calcium pyrophosphate hydrates were applied to the cells.
Conclusions: Crystals extracted from human osteoarthritic knee cartilage induce the production of proinﬂammatory and catabolic mediators
(NO, MMP-13 and PGE2) in human primary chondrocytes and synoviocytes. Synthetic calcium phosphate and pyrophosphate crystals elicit
a similar response in those cells. Our ﬁndings suggest that these crystals could contribute to cartilage degradation and synovitis in OA.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is characterised by articular cartilage
degeneration, synovitis and subchondral bone remodel-
ling1. Chondrocytes play a key role in cartilage degradation
by releasing matrix metalloproteinases (MMPs) and nitric
oxide (NO)2,3. Synovial inﬂammation is implicated in the
signs and symptoms of OA4e6. Synoviocytes release in-
ﬂammatory mediators, including prostaglandin E2 (PGE2),
contributing to signs and symptoms of the disease.
Calcium pyrophosphate dihydrate (CPPD) and basic cal-
cium phosphate (BCP) are commonly deposited in osteoar-
thritic joints. These crystals have been found in the synovial
ﬂuid of 60% of all patients with knee effusions in OA and
over 90% of a small group of patients with grade-4 OA7.
They are associated with cartilage lesion and a severe
form of OA8e10. These crystals have been demonstrated
to induce inﬂammatory response in cells11e13. Further, in-
tra-articular injection of CPPD crystals can exacerbate the
OA progression in rabbit knee joints14. On the basis of
those observations, CPPD and BCP crystals have been as-
sumed to contribute to OA disease progression15.*Address correspondence and reprint requests to: Dr Yu-Zhen
Liu, Department of Bioscience, AstraZeneca R&D Charnwood,
Bakewell Road, Loughborough LE11 5RH, UK. Tel: 44-1509-
645815; Fax: 44-1509-645557; E-mail: yu-zhen.liu@
astrazeneca.com
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1333CPPD exists in two forms: triclinic and monoclinic, gen-
erally abbreviated to t-CPPD and m-CPPD, respectively.
A tetrahydrate also exists and is dimorphic, denoted m-
CPPTa and m-CPPTb16. Characterisation of these forms
in the context of their in vivo prevalence has been fo-
cussed primarily on microscopy and X-ray powder diffrac-
tion (XRPD) studies17,18. Crystal structures have been
determined for t-CPPD19, m-CPPTa20 and m-CPPTb16.
In addition, the crystal growth and dissolution kinetics of
the calcium pyrophosphate hydrate phases have been in-
vestigated21e25, as has the dehydration26. Analysis of sy-
novial ﬂuid and menisci often reveals the presence of
both triclinic and monoclinic forms of CPPD, t-CPPD
predominating27,28.
BCP is a broad term used to describe a number of crys-
tallographically and chemically distinct phases. Therefore
BCP encompasses hydroxyapatite Ca10(PO4)6(OH)2, octa-
calcium phosphate Ca8(HPO4)2(PO4)45H2O and tricalcium
phosphate Ca3(PO4)2. BCP is also synonymous with bi-
phasic calcium phosphate, a mixture of hydroxyapatite
and tricalcium phosphate29. In general, BCP is often insuf-
ﬁciently characterised in the literature. Other phosphate
phases of interest are dicalcium phosphate dihydrate
(DCPD, CaHPO42H2O) and its anhydrate (monatite,
CaHPO4). These phases are known to be intermediates
in the synthesis of hydroxyapatite30,31. DCPD has been ob-
served in synovial tissues and cartilage, and in menisci at
necropsy32,33.
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BCP crystals used the synthetic crystal materials. Studies
of the biological effects of synthetic calcium crystals must
also take into account the existence of several crystalline
phases in natural pathological conditions. The effects of
endogenous crystals from diseased joints have not been
reported. This work was designed to characterise the forms
of crystals from crystalline osteoarthritic joints and compare
the proinﬂammatory and catabolic effects of synthetic and
native calcium crystals in human osteoarthritic chondro-
cytes and synoviocytes.
Materials and methodsSYNTHESIS OF CALCIUM-CONTAINING CRYSTALSAttempted synthesis of BCP followed the method of McCarthy et al.34.
50 ml 0.2 M NaPi, pH 6.7 was added to 42 ml 0.2 M CaCl2 and stirred for
1 h at room temperature. The precipitate was harvested by centrifugation
and washed with water. The crystals were resuspended in 6.7 ml water
and 67 ml of 0.5 M HCl added. The pH was adjusted to between 8.5 and
10 and the suspension stirred overnight. It was then washed with water, steri-
lised by washing in 70% ethanol and freeze dried.
Polymorphs ofCPPDwere synthesisedusingmethodsdescribed byCheng
and Pritzer35. For t-CPPD, the initial solution contained 1 mM CaCl2, 0.1 mM
MgCl2, 0.24 mMNaPPi and 140 mMNaCl, pH 7.4. For m-CPPD, the initial so-
lution contained 1 mM CaCl2, 0.8 mM MgCl2, 0.34 mM NaPPi and 140 mM
NaCl, pH 7.4. m-CPPTb was prepared using the starting solution containing
1.6 mM CaCl2, 0.48 mM NaPPi and 140 mM NaCl, pH 7.4. One litre of each
of the above solutions was prepared and shaken at 37C for 3 weeks. The pre-
cipitate was harvested by centrifugation, washed with water, sterilised by
washing in 70% ethanol and freeze dried for approximately 16 h.
Where indicated, synthetic crystals were reduced in size through crushing
with a pestle and mortar. This process tended to form loose aggregates that
were dispersed by sonicating for 30 s. Initially samples were sterilised and
rendered lipopolysaccharide (LPS) free by heating at 200C for 2 h36. This
baking process was found to change the crystal form hence was only carried
out for the indicated samples.PURIFICATION OF CRYSTALS FROM OSTEOARTHRITIC KNEE
JOINTSCrystals were extracted from the osteoarthritic cartilage using a method
based on Swan et al.37. Human OA cartilage samples were obtained from
patients undergoing total knee replacement operations for OA. Five human
OA cartilage samples had been identiﬁed visually as containing crystals and
used for crystal puriﬁcation. All ﬁve patients had no history of acute pseu-
dogout. Chondrocalcinosis was present on radiographs from two patients.
Thecartilage sampleswerechopped ﬁnely and resuspended in 2.5 volumes
(w/v) of 100 mM 2-(N-morpholino)ethanesulfonic acid (MES), 1 mM dithiothreitol
(DTT), pH 6.5. Papain was added to 10 mg/ml and the suspension incubated at
37C overnight. The suspension was ﬁltered and the ﬁltrate was spun at
4000 rpm for 5 min and the supernatant discarded. The pellet was washed with
water followed by 1% sodium hypochlorate for 2 min and a further water wash.
Thepelletwasﬁnally resuspended in70%ethanol, and freezedried for4 h.Yields
of crystalsobtained by thismethodwere up to 10 mgcrystalsper gramwetweight
tissue.Processingnormal cartilage in parallel withOA tissue did not generate any
detectable crystalline material.CHARACTERISATION OF SYNTHETIC AND PURIFIED
ENDOGENOUS CRYSTALSThe synthetic and extracted samples were characterised using a PANalyt-
ical CubiX PRO X-ray diffractometer of wavelength 1.5418 A˚ (Cu source,
voltage 45 kV, ﬁlament emission 40 mA). Samples were scanned from 2 to
40 2q using a 0.02 step width and a 100 s time count with an X’celerator
detector (active length 2.54 2q). As most previous diffraction studies have
cited diffraction reﬂections in d-spacing, rather than 2q, we continue this con-
vention. It can be noted that d-spacing (d ), and theta (q), are interrelated by
the Bragg equation, nl¼ 2d sin q, where l is the wavelength of the X-rays.CULTURE AND TREATMENT OF PRIMARY CHONDROCYTES
AND SYNOVIOCYTESHuman OA cartilage and synovium were obtained from patients undergo-
ing total knee replacement operations. The patients were taking pain relief
medication (e.g., paracetamol or ibuprofen). Full ethical consent was ob-
tained from all donors and families.To isolate primary chondrocytes, cartilage were stripped from the femoral
condyles and tibial plateaux, cut into ﬁne pieces and digested in growth me-
dia [Dulbecco’s modiﬁed eagles medium supplemented with 10% foetal calf
serum (FCS), penicillin (100 units/ml), streptomycin (100 mg/ml), 2 mM L-glu-
tamine] containing 1 mg/ml collagenase II (Worthington Biochemicals,
CLS-2). After overnight incubation at 37C, the sample was ﬁltered to re-
move undigested cartilage and chondrocyte cells pelleted at 500g for
10 min. Cells were washed with growth medium and pelleted again. Cells
were then grown in monolayer without passaging (5e7 days from isolation)
before being utilised in experiments. A signiﬁcant proportion of the cell prep-
arations from OA cartilage contain crystals. Only the cells free of crystals
were used in this study. The cells were dissociated from growing ﬂasks by
incubating in a small volume of 1 trypsin ethylenediaminetetraacetic acid
(EDTA) for 15 min at 37C after removing the growth medium and washing
with phosphate buffered saline (PBS) (no Ca2þ, no Mg2þ). The cells were
then harvested and plated at a density of 50,000 cells/well in growth medium
in 96-well cell culture plates for experiment.
For preparation of primary synoviocytes, the synovium was cut into small
pieces and digested in growthmedia [Roswell ParkMemorial Institutemedium
(RPMI) 1640 supplemented with 10% FCS, penicillin (100 units/ml), strepto-
mycin (100 mg/ml), 2 mM L-glutamine] containing 1 mg/ml collagenase II. After
the 2-h digestion at 37C, the cell suspension was ﬁltered to remove any un-
digested tissue. The ﬁltered cell suspension was centrifuged at 500g for
10 min. The cells were resuspended into 10 ml of RPMI 1640 (with 2 mM L-glu-
tamine) supplemented with 10% heat-inactivated FCS. Flow cytometry anal-
ysis of the OA synovial cells showed that the cell preparation was
comprised mainly of ﬁbroblast-like synoviocytes with 2e7% macrophages.
Primary cells were then plated in a cell culture ﬂask overnight before being uti-
lised in experiments. The cells were dissociated from growing ﬂasks by a gen-
tle scraping using a cell scraper after removing the growth medium and
washing with PBS (no Ca2þ, no Mg2þ). The cells were then harvested and
plated at a density of 50,000 cells/well in growth medium in 96-well cell culture
plates for experiment.
Following plating in 96-well cell culture plates, the cells were incubated over-
night at 37C. The cell growth medium was then replaced with the fresh growth
medium an hour before treatment with the crystals, interleukin (IL)-1b (CalBio-
chem), Pam3CSK (Invivogen) or anti-toll-like receptor 2 (TLR2) antibody (clone
T2.5, Hycult Biotechnology). At the end of the experiment, the conditionedmedia
from thecellswereharvested for subsequentanalysesand thecell viability tested.DETERMINATION OF MMP-13 PROTEIN AND PGE2 BY
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)Conditioned media from primary chondrocytes and synoviocytes were as-
sayed for MMP-13 and PGE2 using commercially available ELISA kits
(MMP-13 ELISA kit from Amersham Biosciences and PGE2 ELISA kit from
R&D Systems).DETERMINATION OF NITRITE LEVELNO accumulation was measured by the Griess reaction. Fifty micro litres
of conditioned media from primary chondrocytes and synoviocytes was
mixed with 150 ml freshly prepared Griess reagent, comprising equal quanti-
ties of 0.1% (1-naphthyl)ethylenediamide dihydrochloride (Sigma) and 1%
sulfanilamide in 5% orthophosphoric acid (Sigma). The nitrite concentrations
were immediately determined by measuring absorbance at 550 nm.CELL VIABILITY ASSAYCell viability was assessed by the WST-1 assay (cell proliferation reagent
WST fromRoche). WST reagent was added to primary chondrocytes and syn-
oviocytes at the end of experiments. The cells were incubated for 10 min at
37C. Cell activity was determined by measuring absorbance at 440 nm.STATISTICAL ANALYSISAll data are presented as mean S.E.M. The n numbers refer to the sam-
ple number of OA patients tested. Where applicable, the t test for paired
samples was performed for statistical analysis. P-values< 0.05 were consid-
ered signiﬁcant.
ResultsCHARACTERISATION OF SYNTHETIC CALCIUM PHOSPHATE
AND PYROPHOSPHATE CRYSTALSFigure 1(a) and (b) shows the XRPD diffractogram of at-
tempted synthesis of pure t-CPPD and m-CPPD, respectively.
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Fig. 1. X-ray diffractograms of (a) t-CPPD, (b) m-CPPD, (c) m-CPPTb and (d) DCPD.
1335Osteoarthritis and Cartilage Vol. 17, No. 10The diffractogram for m-CPPD shows distinctive strong reﬂec-
tions at 7.29, 4.59 and 3.03 A˚ (asterisked) whilst the pattern
for the triclinic form shows reﬂections at 8.02, 6.99 and
3.23 A˚ (asterisked). These reﬂections are consistent with
those described by other workers and conﬁrm successful syn-
thesis of the pure CPPD forms28,38.
Attempts to synthesise CPPT were also successful as
shown by the X-ray diffraction pattern of the unbaked mate-
rial [Fig. 1(c)]. The distinctive strong reﬂections at 11.33,
3.79 and 3.38 A˚ (asterisked) in the diffraction pattern are
consistent with the b form of calcium pyrophosphate tetra-
hydrate16. However, baking the sample resulted in a phase
change. Assessment of this new phase against potential
phases did not provide a deﬁnitive conﬁrmation of identity,
though dehydration or reduction to calcium phosphate are
probable mechanisms26,39.
The speciﬁc identity of the crystals from the attempted
BCP synthesis was conﬁrmed by XRPD to be DCPD; the
intense reﬂections at 7.58, 4.23 and 3.05 A˚ [asterisked in
Fig. 1(d)] are consistent with literature values40. Baking
the sample gave an X-ray diffractogram consistent with
monatite, CaHPO4
41.
Crystal samples are commonly baked to remove any LPS
contamination that could lead to signalling through the
TLR436. As described above, the process of baking crystals
can change the physical form of the crystals, adding to the
confusion as to the identity of the speciﬁc physical forms af-
fecting cellular signalling. It became apparent that there was
no signiﬁcant level of LPS contamination in the unbaked
crystal samples, as measured using a TLR4 reporter cell
line.
Optical microscopy reveals crystals were heterogeneous
in size ranging from >1 mm (the optical limit of the micro-
scope used) to 50 mm (Fig. 2). m-CPPD [Fig. 2(a)] and
t-CPPD [Fig. 2(b)] were both ordered and needle like struc-
tures. DCPD [Fig. 2(c)] and m-CPPTb [Fig. 2(d)] were less
well ordered. Crushing the crystals with a pestle and mortar
effectively reduced the crystal size as exempliﬁed by
crushed m-CPPTb [Fig. 2(e)].CHARACTERISATION OF CRYSTALS FROM THE
OSTEOARTHRITIC KNEE JOINTWe observed that some OA articular cartilage samples
contained visible crystals. Figure 3 shows the picture ofa representative crystalline cartilage sample from OA
knee. The crystals appeared as white precipitates on the
cartilage surface. We have also observed that intracellular
crystals were present in OA synoviocytes, indicating that
phagocytosis of crystals occurred in the OA joint (Fig. 4).
The crystalline material extracted from OA cartilage
[Fig. 2(f)] resembled the needle like t-CPPD and m-CPPD
although the crystals are smaller (up to 10 mm) than the syn-
thetic material. XRPD was performed to obtain more deﬁn-
itive proof of the identity of this crystalline material.
Figure 5 shows the XRPD pattern of extracted material.
Remarkably, the ratio of m-CCPD to t-CPPD was extremely
consistent across all four donors. It should be noted that the
extraction technique is reported not to affect the extraction
of either hydroxyapatite or CPPD from cartilage37. The dif-
fractograms of the extracted material were interrogated for
any evidence of other crystalline phases other than
CPPD, such as any BCP phases. All reﬂections in the dif-
fractograms of the extracted materials could be accounted
for by either m-CCPD or t-CPPD; no BCP was present.PROINFLAMMATORY AND CATABOLIC EFFECTS OF
SYNTHETIC CALCIUM PHOSPHATE AND PYROPHOSPHATE
CRYSTALS IN PRIMARY CHONDROCYTES AND
SYNOVIOCYTESHere, we showed that the catabolic activity of some syn-
thetic crystal forms depends on the size; crushing m-CPPTb
crystals increased the activity (Fig. 6). Our synthetic
m-CPPD and t-CPPD crystals induced NO and MMP-13
release in human OA chondrocytes in a dose-dependent
manner [Fig. 7(a and b)]. Synthetic DCPD crystals also
showed a catabolic activity in human OA chondrocytes
(Fig. 7). None of the crystals showed cytotoxic effects on
the cell by measuring WST-1 activity. The observed crys-
tal-induced response in the cells appeared speciﬁc as there
were no induction of NO in the cells in response to other
particles including iron, SiO2, ground glass and melanine
(data not shown).
A recent study reported that synthetic BCP induces PGE2
synthesis in human OA synovial ﬁbroblasts42. In this study,
DCPD crystals induced up to 70-fold upregulation of PGE2
release in human OA synoviocytes [Fig. 7(c)]. The synthetic
pyrophosphate crystals also strongly increased PGE2
release in the cells.
Fig. 2. Micrographs of the calcium-containing crystals that have been generated using the methods described in the text: (a), m-CPPD;
(b), t-CPPD; (c), DCPD; (d), m-CPPTb; (e), crushed m-CPPTb and (f), extract from OA cartilage. The scale bar represents 25 mm.
1336 Y. Z. Liu et al.: Contribution of calcium-containing crystals in OAPROINFLAMMATORY AND CATABOLIC EFFECTS OF
CRYSTALS FROM THE OSTEOARTHRITIC KNEE JOINT
IN PRIMARY CHONDROCYTES AND SYNOVIOCYTESThe extracted crystals from OA crystalline cartilage sam-
ples were tested in human OA chondrocytes and synovio-
cytes. The endogenous crystals induced NO, MMP-13
and PGE2 production in OA chondrocytes in a dose-depen-
dent manner (Fig. 8). Similarly, the crystals increased PGE2
release in OA synoviocytes [Fig. 8(d)]. Interestingly, the re-
sponse is similar to the well established potent catabolic cy-
tokine IL-1b (Fig. 8). In order to exclude that the catabolicFig. 3. An image of human femoral condyles that has been used in
this study highlighting the cartilage and the exposed bone. The ar-
row indicates visible crystal deposition on the surface of the
cartilage.response is mediated by other biological materials co-ex-
tracted with the crystals from OA cartilage, we processed
OA cartilage with little crystal content and normal cartilage
through crystal puriﬁcation procedure and tested the end
product. Neither of these samples showed similar catabolic
response to the ones from crystalline OA cartilage. We
have also conﬁrmed that the physical interaction between
the crystals and cells was required for the catabolic re-
sponse by treating cells growing on the permeable mem-
brane ﬁlters with crystals basolaterally without direct
contact. Under those conditions, no catabolic responseFig. 4. An image of primary human OA synovoial cells derived from
the OA synovium. The inset is a view of the cell cytoplasm that
contains crystals.
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1337Osteoarthritis and Cartilage Vol. 17, No. 10was observed. The crystals did not show cytotoxic effects
(data not shown).THE ROLE OF TLR2 IN CALCIUM CRYSTAL-MEDIATED NO
INDUCTION IN CHONDROCYTESSynthetic m-CPPD and triclinic monosodium urate
(t-MSU) crystals have been reported to use TLR2-mediate
signalling in bovine chondrocytes to trigger NO produc-
tion36. The same study also reported that TLR2 receptor
is expressed in human primary articular chondrocytes;
thus the crystals may induce catabolic responses via
TLR2 in human OA chondrocytes. To explore the role of
TLR2 in crystal-mediated response in OA chondrocytes,
we used a TLR2 blocking antibody and examined the anti-
body mediated inhibition on both crystal-induced and TLR2
synthetic ligand Pam3CSK induced NO production (Fig. 9).
Pam3CSK induced NO production, indicating the presence
of functional TLR2 in human OA chondrocytes. As ex-
pected, the TLR2 blocking antibody signiﬁcantly inhibited
the response mediated by Pam3CSK. However, the block-
ing antibody failed to reduce the response mediated by ei-
ther the endogenous crystals from OA knee cartilage or0
5
10
15
20
25
V 0.125 0.25 0.5 1
m-CPPTbeta (mg/ml)
N
i
t
r
i
t
e
 
(
µ
M
)
Crushed
Uncrushed
Fig. 6. Crushing of synthetic m-CPPTb enhanced the catabolic ef-
fects in primary OA chondrocytes. Primary OA chondrocytes from
three different donors were treated with crushed or uncrushed m-
CPPTb crystals for 24 h. The production of NO (n¼ 3) over the
24 h treatment per iod was determined. Bars represent
mean S.E.M.our synthetic crystals (Fig. 9). We also tested our synthetic
t-CPPD, m-CPPD and DCPD crystals in our human TLR2
or TLR2/6 overexpressed recombinant HEK 293 cells.
The crystals did not activate the human TLR2 receptors
(data not shown). Our data suggest that CPPD crystals
are unlikely to be ligands of human TLR2 receptors.Discussion
Synthetic calcium phosphate and pyrophosphate crystals
have been assessed and compared with previous studies
reported in the literature. We have sought to be very precise
in our characterisation since we found the literature charac-
terisation confusing. For example BCP is a general term
and we have been unable to obtain a comprehensive list
of phases that term includes, and characterisation by
XRPD is variable. Furthermore due to the similarity of
CPPD and CPPT nomenclature, some confusion has oc-
curred; for example the incorrect description of o-CPPT as
being the dihydrate38. The literature is further confused by
the use of the term ‘‘dehydrate’’ for ‘‘dihydrate’’43,44. We be-
lieve this may be a consequence of automated spell check-
ers. It seems that we are still some way away from fully
understanding the ‘‘complex crystal chemistry of the cal-
cium pyrophosphates’’39.
In this study we conﬁrmed that we were successful in pro-
ducing synthetic samples of m-CPPD, t-CPPD and m-
CPPTb. We were unsuccessful in conﬁrming the identity
of material formed by baking m-CPPTb. The formation of
DCPD instead of one of the more common forms of BCP
is potentially as a result of pH drift during the synthesis45.
The synthetic crystals were larger than those isolated
from OA knee tissue. Crushing of m-CPPTb crystals gener-
ated a sample more akin to the size of the native CPPD
crystals. Biological activity could only be seen when the
m-CPPTb crystals were reduced in size, hence the size of
the crystals formed can be a determinant in their biological
activity. This response to size is not simply a particle size
effect; addition of inert material consisting of differing chem-
ical and physical compositions but a similar particle size to
the calcium crystals, did not generate a biological response.
In contrast, the observed cellular response to CPPD was
not dependent on particle size.
We have frequently observed that some OA articular car-
tilage samples contain visible crystals. The extracted
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Fig. 8. Induction of NO (a), MMP-13 (b) and PGE2 (c) release in pri-
mary OA chondrocytes and PGE2 (d) release in primary OA syno-
viocytes by puriﬁed endogenous OA knee joint crystals. The
crystals were prepared from ﬁve different OA crystalline cartilage
samples and tested. The cells from four to eight different donors
were treated with the puriﬁed crystals or IL-1b (0.1 ng/ml) for
24 h. The production of NO (n¼ 8), MMP-13 (n¼ 5) and PGE2
(n¼ 4) from chondrocytes and PGE2 (n¼ 6) from synoviocytes
over the 24 h treatment period was determined. Bars represent
mean S.E.M.
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Fig. 7. Induction of NO (a) and MMP-13 (b) in primary OA chondro-
cytes and PGE2 (c) release in primary OA synoviocytes by syn-
thetic crushed m-CPPTb, t-CPPD, m-CPPD and DCPD crystals.
The cells from three to ﬁve different donors were treated with
crushed m-CPPTb, t-CPPD, m-CPPD or DCPD crystals for 24 h.
The production of NO (n¼ 5), MMP-13 (n¼ 3) and PGE2 (n¼ 5)
over the 24 h treatment period was determined. Bars represent
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1338 Y. Z. Liu et al.: Contribution of calcium-containing crystals in OAmaterial from four donors characterised, gave very similar
ratios of m-CPPD and t-CPPD. This suggests either that
a biological mechanism is at work resulting in this, or that
the extraction process gives rise to this ratio. Whilst not ex-
plicit in Mandel’s inference of a crystallographic relationship
between the two forms38, the possibility of epitaxial growth
as an explanation of the ratio is a reasonable one; epitaxy
refers to the situation where a growth face of one crystal
is sufﬁciently similar with respect to atomic positions to
the growth face of a second phase, that the second phase
grows concurrently. In the case of CPPD, as one hydrate
grows, the other hydrate phase grows with it, thus resulting
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Fig. 9. Calcium phosphate and pyrophosphate crystal-induced NO
release is not TLR2 dependent. Primary OA chondrocytes from
three different donors were pre-treated with a TLR2 blocking anti-
body T2.5 at 100 mg/ml or IgG1 control for an hour before addition
of synthetic and endogenous crystals (0.3 mg/ml) or the TLR2 li-
gand Pam3CSK (1 mg/ml). The endogenous crystals were prepared
from ﬁve different OA crystalline cartilage samples and named as
D1, D2, D3, D4 and D5. Following 24 h treatment the production
of NO (n¼ 3) over the treatment period was determined. Bars rep-
resent mean S.E.M. *P< 0.05, signiﬁcantly different from corre-
sponding IgG1 value.
1339Osteoarthritis and Cartilage Vol. 17, No. 10in a regularly observed ratio between the phases. No BCP
crystals were detected in the puriﬁed OA cartilage crystal
samples. This contrasts with reports that BCP crystals are
frequently detected in OA synovial ﬂuid46. It suggests that
BCP crystals in synovial ﬂuid are probably derived from
bone remodelling in the OA joint.
Synthetic calcium phosphate and pyrophosphate crystals
have been reported to induce proinﬂammatory response in
various cell types including human synovial ﬁbroblasts,
monocytes and bovine chondrocytes. However, limited
studies have been carried out in primary human OA chon-
drocytes. Our studies further conﬁrm the biological activity
of calcium crystals in human primary OA chondrocytes
and synoviacytes. Of interest is the activity of calcium-con-
taining crystals depending on the size. For example, crush-
ing of m-CPPTb crystals leads to the increase of activity.
The underlying mechanism for the size-dependent effects
is unclear. A previous study has reported the size-depen-
dent calcium pyrophosphate crystal phagocytosis in
polymorphonuclear leukocytes47. Since crystalecell inter-
actions and inﬂammatory responses are inﬂuenced by crys-
tal size and morphology, standardisation of methods of
preparing and characterising calcium crystals is, therefore,
important, particularly when analysing and comparing re-
sults from different research laboratories.
A strong catabolic effect in human OA chondrocytes has
been observed with the naturally occurring crystals. In our
laboratory, we have tested a number of known catabolic fac-
tors (such as IL-1, IL-17, IL-18, tumour necrosis factor-alpha,
oncostatin M, transforming growth factor-beta and various ﬁ-
bronectin fragments) in OA cells and have noted that IL-1a
and IL-1b are the most potent and strongest stimuli. In this
study, we have found that CPPD crystals can achieve similar
efﬁcacy to IL-1 in inducing NO, MMP-13 and PGE2 release.
Some progress has been made in understanding the mo-
lecular mechanisms of calcium crystal-mediated cell activa-
tion48. Intracellular mitogen-activated protein kinase
cascade appears to mediate the crystal-induced cellularresponse13,49. Crystals have been shown to be phagocy-
tosed by cultured synoviocyte and consequently stimulate
the release of MMPs and prostaglandins50. Our ﬁnding
that OA synovial cells from OA joints contain crystals sup-
ports that the crystal phagocytosis can occur in vivo. The di-
rect effects of CPPD crystals on cells may also involve an
interaction between crystals and cell surface receptors. It
has been reported that CPPD crystals use TLR2 receptors
in bovine chondrocytes to trigger NO production36. We have
examined the role of TLR2 receptors in crystal-mediated
cell activation in human primary cell system. In contrast to
the previous ﬁnding, our data do not support a role of
TLR2 in mediating the response induced by both synthetic
and endogenous crystals. The reason for this discrepancy
is not clear. It might be related to the difference of crystal
preparation or species differences. The activation of bovine
TLR2 receptors by CPPD crystals might not be directly
translated to the human system.
It is well established that the calcium-containing crystals
are most commonly associated with joint diseases. The rela-
tionship between calcium crystal deposition and OA remains
unclear, controversial and a difﬁcult one to approach. There
are two main hypotheses: one is that calcium crystals cause
or worsen OA12e18; the opposite hypothesis is that OA
causes or worsens calcium crystal deposition51e55. Here,
we have shown that crystals from OA knee joints strongly in-
duce NO, MMP-13 and PGE2 production from primary chon-
drocytes and synoviocyte, suggesting that the naturally
occurring calcium crystals may contribute to cartilage degra-
dation and synovitis in OA. It is unlikely that those biologi-
cally active calcium crystals present in the OA joints are
just a benign bystander or a disease marker.Conﬂict of interest
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